Immunovia (NASDAQ STOCKHOLM: IMMNOV), a Sweden-based pancreatic cancer diagnostics company, announced on Thursday that it will present an update on its next-generation test at the annual meeting of the PRECEDE pancreatic cancer research consortium.

The PRECEDE Consortium is a partnership of 51 pancreatic centres globally carrying out unprecedented research for the early detection of pancreatic cancer in individuals with increased risk of the disease.

Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation. As reported by the company in an August 1, 2024 press release, the test demonstrated superior performance, with sensitivity of 85 percent and specificity of 98 percent, in the model-development study of 623 patient samples. In addition to presenting data on its next-generation test, Immunovia leaders will meet with PRECEDE researchers to discuss current research collaborations and future studies.

Jeff Borcherding, Immunovia chief executive officer, said: "Our collaboration with PRECEDE has proven tremendously valuable. PRECEDE researchers provided hundreds of blood samples to support the current clinical validation study of our next-generation test. We are excited to update Consortium members and discuss ways we can collaborate to generate additional data on the accuracy and clinical use of our test. It's energizing to partner with a group that is so passionate about improving pancreatic cancer survival through early detection."